Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
NMTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $1.39
Previous CloseN/A
Volume212.44K
Average Volume (3M)200.15K
Market Cap
$40.40M
Enterprise Value$25.44M
Total Cash (Recent Filing)$1.32M
Total Debt (Recent Filing)$311.41K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 14, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding49,817,837
10 Day Avg. Volume221,915
30 Day Avg. Volume200,151
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue4.42
Enterprise Value/Gross Profit8.15
Enterprise Value/Ebitda-4.45
Forecast
1Y Price Target
$1.45Price Target Upside90.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
NeuroOne Medical Technologies News
NMTC FAQ
What was NeuroOne Medical Technologies’s price range in the past 12 months?
NeuroOne Medical Technologies lowest stock price was $0.40 and its highest was $1.39 in the past 12 months.
What is NeuroOne Medical Technologies’s market cap?
NeuroOne Medical Technologies’s market cap is $40.40M.
When is NeuroOne Medical Technologies’s upcoming earnings report date?
NeuroOne Medical Technologies’s upcoming earnings report date is Aug 14, 2025 which is in 6 days.
How were NeuroOne Medical Technologies’s earnings last quarter?
NeuroOne Medical Technologies released its earnings results on May 13, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is NeuroOne Medical Technologies overvalued?
According to Wall Street analysts NeuroOne Medical Technologies’s price is currently Undervalued.
Does NeuroOne Medical Technologies pay dividends?
NeuroOne Medical Technologies does not currently pay dividends.
What is NeuroOne Medical Technologies’s EPS estimate?
NeuroOne Medical Technologies’s EPS estimate is -0.05.
How many shares outstanding does NeuroOne Medical Technologies have?
NeuroOne Medical Technologies has 49,817,837 shares outstanding.
What happened to NeuroOne Medical Technologies’s price movement after its last earnings report?
NeuroOne Medical Technologies reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of NeuroOne Medical Technologies?
Currently, no hedge funds are holding shares in NMTC
NeuroOne Medical Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.45 (90.79% Upside)
$1.45 (90.79% Upside)
Blogger Sentiment
Bullish
NMTC Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $18.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.20%
12-Months-Change
Fundamentals
Return on Equity
-265.18%
Trailing 12-Months
Asset Growth
-17.39%
Trailing 12-Months
Company Description
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NMTC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights a strong growth trajectory with significant increases in revenue and gross margins, successful capital raise, and positive clinical outcomes. However, there are challenges in maintaining revenue growth on a quarterly basis and the company continues to operate at a net loss, albeit improved. Overall, the company is well-positioned for future growth with new applications and strategic partnerships.View all NMTC earnings summariesTechnical Analysis
PAVmed
―
Vicarious Surgical
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
11.51% Insiders
2.76% Mutual Funds
0.10% Other Institutional Investors
83.22% Public Companies and
Individual Investors